Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aduro launching IPO

This article was originally published in Scrip

Executive Summary

Berkeley, California-based Aduro Biotech is planning to raise $86m through an initial public offering. The biotech, which is developing an immunotherapy for pancreatic cancer, will debut on Nasdaq under the symbol ADRO. Founded in 2000, Aduro initially filed its plans confidentially with the Securities and Exchange Commission (SEC) back in December 2014. No pricing terms were disclosed. Bank of America Merrill Lynch and Leerink Partners are the joint bookrunners on the deal. Aduro is developing CRS-207, a live attenuated strain of Listeria that Aduro has engineered to express human mesothelin, in combination with its GVAX Pancreas vaccine as a treatment for pancreatic cancer. It is currently in Phase IIb trials. A Phase II trial of the combination was stopped early in January 2014 on the strength of the data after a pre-planned interim analysis. Aduro has an ongoing partnership with Johnson & Johnson company Janssen Biotech for a number of products leveraging Aduro's technology.

You may also be interested in...

Femtech Presents Enticing Market Opportunity

A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.

Execs On The Move, Sep 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Snapshot: September Highlights

A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts